Table 1.
No. of patients 257  
Dates of transplant March 1995-January 2000  
Mean follow-up (range) (mo) 12  (1-60)  
Median age (range) (y) 42  (16-63)  
Diagnosis  
 AML/ALL 123  (47.8%) 
 CML CP1 65  (25.3%)  
 NHL/CLL 29  (11.3%) 
 MM 22  (8.6%)  
 MDS 18  (7%)  
Phase of disease  
 Early 143  (55.6%)  
 Advanced 114  (44.4%)  
Sex  
 F to M 61  (23.7%)  
 M to M 80  (31.1%)  
 F to F 53  (20.6%)  
 M to F 55  (21.4%) 
Cytomegalovirus serology  
 D and R negative 29  (11.3%) 
 D and/or R positive 212  (82.5%)  
 D or R NA 16  (6.2%)  
ABO incompatibility  
 Major 48  (18.7%) 
Myeloablative regimen  
 TBI based 140  (54.5%)  
 Bu based 117  (45.5%)  
GVHD prophylaxis  
 CsA + PDN or MTX 169  (65.8%)  
 CsA 82  (31.9%)  
 None 6  (2.3%)  
Cell content of the graft* (mean and range)  
 CD34+ cells 4  (0.6-15) 
 CD3+ cells 0.3  (0-2.8)  
G-CSF posttransplant 73  (28.4%)  
Cryopreservation 72  (28%) 
No. of patients 257  
Dates of transplant March 1995-January 2000  
Mean follow-up (range) (mo) 12  (1-60)  
Median age (range) (y) 42  (16-63)  
Diagnosis  
 AML/ALL 123  (47.8%) 
 CML CP1 65  (25.3%)  
 NHL/CLL 29  (11.3%) 
 MM 22  (8.6%)  
 MDS 18  (7%)  
Phase of disease  
 Early 143  (55.6%)  
 Advanced 114  (44.4%)  
Sex  
 F to M 61  (23.7%)  
 M to M 80  (31.1%)  
 F to F 53  (20.6%)  
 M to F 55  (21.4%) 
Cytomegalovirus serology  
 D and R negative 29  (11.3%) 
 D and/or R positive 212  (82.5%)  
 D or R NA 16  (6.2%)  
ABO incompatibility  
 Major 48  (18.7%) 
Myeloablative regimen  
 TBI based 140  (54.5%)  
 Bu based 117  (45.5%)  
GVHD prophylaxis  
 CsA + PDN or MTX 169  (65.8%)  
 CsA 82  (31.9%)  
 None 6  (2.3%)  
Cell content of the graft* (mean and range)  
 CD34+ cells 4  (0.6-15) 
 CD3+ cells 0.3  (0-2.8)  
G-CSF posttransplant 73  (28.4%)  
Cryopreservation 72  (28%) 

AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodisplastic syndrome; F, female; M, male; D, donor; R, recipient; NA, not available; TBI, total body irradiation; Bu, busulphan; GVHD, graft-versus-host disease; CsA, cyclosporine A; PDN, prednisone; MTX, methotrexate; G-CSF, granulocyte colony-stimulating factor.

*

×106/kg.

or Create an Account

Close Modal
Close Modal